Charles River Laboratories International, Inc. (NYSE:CRL) Shares Bought by Mawer Investment Management Ltd.

Mawer Investment Management Ltd. raised its holdings in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 14.1% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 46,629 shares of the medical research company’s stock after acquiring an additional 5,769 shares during the period. Mawer Investment Management Ltd.’s holdings in Charles River Laboratories International were worth $8,608,000 at the end of the most recent quarter.

Several other large investors have also made changes to their positions in the business. Virtu Financial LLC acquired a new position in Charles River Laboratories International during the third quarter valued at $601,000. JPMorgan Chase & Co. lifted its holdings in shares of Charles River Laboratories International by 21.6% in the 3rd quarter. JPMorgan Chase & Co. now owns 482,745 shares of the medical research company’s stock valued at $95,086,000 after buying an additional 85,759 shares during the period. State Street Corp boosted its stake in shares of Charles River Laboratories International by 2.0% in the third quarter. State Street Corp now owns 2,130,279 shares of the medical research company’s stock worth $419,601,000 after buying an additional 41,421 shares during the last quarter. Janus Henderson Group PLC grew its holdings in Charles River Laboratories International by 7.6% during the third quarter. Janus Henderson Group PLC now owns 46,018 shares of the medical research company’s stock worth $9,064,000 after acquiring an additional 3,268 shares during the period. Finally, Neo Ivy Capital Management purchased a new position in Charles River Laboratories International during the third quarter valued at approximately $966,000. 98.91% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Charles River Laboratories International

In related news, COO Birgit Girshick acquired 1,514 shares of Charles River Laboratories International stock in a transaction that occurred on Thursday, February 20th. The shares were purchased at an average cost of $164.63 per share, for a total transaction of $249,249.82. Following the acquisition, the chief operating officer now owns 55,058 shares in the company, valued at approximately $9,064,198.54. This represents a 2.83 % increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CEO James C. Foster purchased 6,075 shares of the stock in a transaction dated Thursday, February 20th. The shares were purchased at an average price of $165.01 per share, with a total value of $1,002,435.75. Following the completion of the transaction, the chief executive officer now owns 183,639 shares of the company’s stock, valued at approximately $30,302,271.39. This trade represents a 3.42 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 1.30% of the stock is owned by insiders.

Charles River Laboratories International Stock Down 1.6 %

Shares of CRL opened at $155.60 on Friday. The stock has a 50 day moving average price of $164.69 and a 200 day moving average price of $182.68. Charles River Laboratories International, Inc. has a one year low of $150.79 and a one year high of $273.32. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.14 and a current ratio of 1.41. The stock has a market capitalization of $7.96 billion, a price-to-earnings ratio of 1,037.35, a PEG ratio of 4.54 and a beta of 1.45.

Charles River Laboratories International (NYSE:CRL) last released its earnings results on Wednesday, February 19th. The medical research company reported $2.66 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.50 by $0.16. The business had revenue of $1 billion during the quarter, compared to analyst estimates of $983.63 million. Charles River Laboratories International had a net margin of 0.52% and a return on equity of 14.69%. The company’s revenue for the quarter was down 1.1% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $2.46 earnings per share. Equities research analysts forecast that Charles River Laboratories International, Inc. will post 9.36 earnings per share for the current fiscal year.

Analyst Ratings Changes

CRL has been the topic of several recent research reports. Bank of America lowered their price objective on Charles River Laboratories International from $220.00 to $210.00 and set a “neutral” rating on the stock in a research report on Friday, December 13th. The Goldman Sachs Group lowered shares of Charles River Laboratories International from a “buy” rating to a “neutral” rating and dropped their price target for the company from $190.00 to $170.00 in a research report on Friday, March 21st. Barclays decreased their price objective on shares of Charles River Laboratories International from $205.00 to $166.00 and set an “equal weight” rating for the company in a research report on Tuesday, February 18th. William Blair cut Charles River Laboratories International from an “outperform” rating to a “market perform” rating in a research report on Wednesday, January 22nd. Finally, JPMorgan Chase & Co. reduced their price target on Charles River Laboratories International from $175.00 to $165.00 and set a “neutral” rating for the company in a report on Thursday, February 20th. One research analyst has rated the stock with a sell rating and sixteen have assigned a hold rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $189.77.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).